Implementing risk based care for CKD in Manitoba

Navdeep Tangri MD PhD FRCPC Associate Professor, Division of Nephrology Dept. of Medicine and Dept. of Community Health Sciences Seven Oaks General Hospital, University of Manitoba Adjunct Associate Professor, Division of Nephrology Tufts Medical Center, Tufts University



UNIVERSITY of Manitoba

Chronic Kidney Disease

- Affects one in 10 individuals in Canada
- Disproportionately affects the elderly
- Disproportionately affects the aboriginal population
- Leads to kidney failure, cardiovascular disease, and higher risks of early death

ORIGINAL ARTICLE

Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization

Alan S. Go, M.D., Glenn M. Chertow, M.D., M.P.H., Dongjie Fan, M.S.P.H., Charles E. McCulloch, Ph.D., and Chi-yuan Hsu, M.D.



Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. Erratum in: N Engl J Med. 2008;18(4):4.

Chronic Kidney Disease and Kidney Failure



Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011 Jul;80(1):93-104.

KDIGO CKD Staging (2012-)

Composite Ranking for				Albuminuria Stages, Description and Range (mg/g)				
				А	.1	A2	Æ	\3
a	nd Alb	ouminuria	optimal and high-normal		high	very high and nephrotic		
	KDIG	O 2009	<10	10-29	30-299	300- 1999	<u>></u> 2000	
	C1	high and	>105					
	GI	optimal	90-104					
GFR		G2 mild –	75-89					
Stages, Descrip-	62		60-74					
tion and Range (mL/min/ 1.73m ²)	G3a	mild- moderate	45-59					
	G3b	moderate- severe	30-44					
	G4	severe	15-29					
	G5	kidney failure	<15					

Levey AS, Tangri N, Stevens LA. Classification of chronic kidney disease: a step forward. Ann Intern Med. 2011 Jan 4;154(1):65-7.

Why risk prediction

- Early and appropriate nephrology care
- Prognostic Information for patient and provider
- Clinical trial enrollment
- Dialysis resource management

Ideal Model

- Across spectrum of chronic kidney disease
- Electronic ascertainment and reporting
- Improve discrimination and reclassification beyond standard of care
- Externally validated in diverse patient populations



Report Status: Final LAST NAME, FIRST NAME

Patient Information	Specimen Information	Client Information	
LAST NAME, FIRST NAME	Specimen : 123456789	Client #: 11223344 L113XXX	
DOB : 01/01/1900 Age : 00	Requisition: 1234567	LAST NAME, FIRST NAME, MD	
Gender: M Fasting: Y	Collected : 10/10/2010	FAMILY PRACTICE ASSOCIATES	
Phone : 800-555-1212	Received : 10/10/2010	1234 MAIN STREET	
Patient ID: 12345	Reported : 10/11/2010	TOWN, CITY, 123456	
Serum Tests			
Creatinine	154	(Normal <90)	
eGFR (Non-AA)	39ml/min	(Normal >60ml/min)	
Urine Tests			
Albumin Creatinine Ratio	20mg/mmol (Normal <2.8 mg/mmol)		
Kidney Failure Risk			
2 years	2.8%		
5 years	8.9%		

*Interpretation

ONLINE FIRST

A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure

Navdeep Tangri, MD, FRCPC
Lesley A. Stevens, MD, MS, FRCPC
John Criffith, PhD
Hocine Tighiouart, MS
Ognjenka Djurdjev, MSc
David Naimark, MD, FRCPC
Adeera Levin, MD, FRCPC
Andrew S. Levey, MD

N ESTIMATED 23 MILLION people in the United States (11.5% of the adult population) have chronic kidney disease (CKD) and are at increased risk for cardiovascular events and progression to kidney failure.1-3 Similar estimates of burden of disease have been reported around the world.º Although there are proven therapies to improve outcomes in patients with progressive kidney disease, these therapies may also cause harm and add cost. Clinical decision making for CKD is challenging due to the heterogeneity of kidney diseases, variability in rates of disease progression, and the competing risk of cardiovascular mortality.7,8 Accurate prediction of risk could facilitate individualized decision making, enabling early and appropriate patient care.9,10

Currently, there are no widely accepted predictive instruments for CKD progression; therefore, physicians must make ad hoc decisions about which patients to treat, risking delays in treatment in those who ultimately progress to kidney failure, or unnecessary treatment in those who do not progress. The severity of CKD has been recommended to guide treatment-related de-

See related articles.

Context Chronic kidney disease (CKD) is common. Kidney disease severity can be classified by estimated giomerular filtration rate (GFR) and albuminuria, but more accurate information regarding risk for progression to kidney failure is required for clinical decisions about testing, treatment, and referral.

Objective To develop and validate predictive models for progression of CKD.

Design, Setting, and Participants Development and validation of prediction models using demographic, clinical, and laboratory data from 2 independent Canadian cohorts of patients with CKD stages 3 to 5 (estimated GFR, 10-59 mL/min/1.73 m²) who were referred to nephrologists between April 1, 2001, and December 31, 2008. Models were developed using Cox proportional hazards regression methods and evaluated using C statistics and integrated discrimination improvement for discrimination, calibration plots and Akalke Information Criterion for goodness of fit, and net reclassification improvement (NRI) at 1, 3, and 5 years.

Main Outcome Measure Kidney failure, defined as need for dialysis or preemptive kidney transplantation.

Results The development and validation cohorts included 3449 patients (386 with Iddney failure [11%]) and 4942 patients (1177 with Iddney failure [24%]), respectively. The most accurate model Included age, sex, estimated GFR, albuminuira, serum calclum, serum phosphate, serum bicarbonate, and serum albumin (C statistic, 0.917; 95% confidence interval [CI], 0.901-0.933 in the development cohort and 0.841; 95% CI, 0.825-0.857 in the validation cohort). In the validation cohort, this model was more accurate than a simpler model that included age, sex, estimated GFR, and albuminuita (integrated discrimination improvement, 3.2%; 95% CI, 2.4%-4.2%; calibration [Nam and D'Agostino χ^2 statistic, 19 vs 32]; and reclassification for CKD stage 3 [NRI, 8.0%; 95% CI, 2.1%-13.9%] and for CKD stage 4 [NRI, 4.1%; 95% CI, -0.5% to 8.8%]).

Conclusion A model using routinely obtained laboratory tests can accurately predict progression to kidney failure in patients with CKD stages 3 to 5.

JAMA. 2011;305(15):doi:10.1001/jama.2011.451 www.jama.com

cisions.¹¹ Severity is commonly staged according to the level of glomerular filtration rate (GFR) estimated from serum creatinine. Reporting estimated GFR when serum creatinine is measured has increased awareness of CKD and referrals to nephrologists, but estimated GFR is not sufficient for clinical decision making.^{12,13}

Recent studies have shown that albuminuria provides additional prognostic information for progression to kidney failure.¹⁴ Some studies have examined the use of estimated GFR and albuminuria in prediction models, with additional clinical and laboratory data, but these models are either specific to a particular type of kidney disease or not externally validated.^{7,15-18} The ideal model to

Author Affiliations: Department of Medicine (Drs Tangrl, Stevens, and Levey) and Biostatistics Research Center, Turth Chincal and Transdational Science Institute (Dr Griffith and Mr Tighiouart), Tufts Medical Center, Boston, Massachusetts, Department of Medicine, University of British Columbia, and British Columbia Provincall Renal Agency, Vancouver, British Columbia, Conada (Dr Levin and Mc Djurdjev); and Department of Medicine, Sumybrook Hospital, University of Toronto, Toronto, Ontario, Canada (Dr Natmark). Corresponding Authon: Nandeep Tangri, MD, FRCPC, Department of Medicine, Tufts Medical Center, 800 Washington St, PO Box 331, Boston, MA 02111 (Intangribit Uthrendcalcenter cog).



Published Online First April 11, 2011

Available at www.jama.com

A prediction model for progression of CKD to Kidney Failure

- Patients with CKD Stages 3 5
- Followed by nephrologists in Ontario and British Columbia, Canada
- 8,391 participants with 1,563 kidney failure events
- Multiple lab based prediction models

Kidney Failure Risk Equation (KFRE)

- We developed laboratory based prediction models that accurately predict the progression of CKD (C statistics 0.84 – 0.91)
- Our preferred models use routinely collected laboratory data
 - 3 variable KFRE Age, Sex, eGFR
 - 4 variable KFRE Age, Sex, eGFR, ACR
 - 8 variable KFRE + Calcium, Phosphorous,
 Bicarbonate and Albumin



Knowledge Translation

eEquation. Applying the Five Year Kidney Failure Risk Prediction to an Individual Patient

The equation of the five year kidney failure risk predictor is:

$$P = 1 \cdot S_0(t)^{\exp f(x)}$$

 $= 1 - S_{ave}(t=1826)^{expf(X)-f_0(x)}$

 $=1-S_{ave}(t=1826)**exp\{-0.49360*[(GFR/5)-7.22]+0.16117*(male-0.56)+0.35066*[ln(ACR)-5.2775]-0.19883*[(age/10)-7.04]-0.33867*(albumin-3.99)+0.24197*(phosphorous-3.93)-0.07429*(bicarbonate-25.54)-0.22129*(calcium-9.35)\}$

= 0.07

	(Ту	pe Over Placeholder Values in	1
Risk Factor	Units	Each Cell)	Notes
Age	years	50	
Sex	male (m) or female (f)	m	
Estimated GFR	ml/min/1.73 m2	30	
Urine Albumin Creatinine Ratio	mg/g	50	
Calcium	mg/dl	9.8	
Phosphorous	mg/dl	3.8	
Albumin	g/dl	4	
Bicarbonate	meq/l	26	
Five year risk of kidney failure		10.7%	

Knowledge Translation



Knowledge Translation - Output

Cancel	к	9:02 PM *	37% 🗉
Question Summary			
Gender?	Male		
Age?	56 Years	Results	
eGFR?	29 mL/min/1.73	Risk of progression to kidney failure requiring dialysis or transplantation	
Urine Albumin Creatinine Ratio?	60 mg/g	Over 2-Years:	
Serum Calcium?	2 mmol/L	17.3 %	
Serum Phosphorous?	2 mmol/L	Over 5-Years:	
Serum Bicarbonate?	19 mEq/L	46.6 %	
Serum Albumin?	35 g/L	For patients with CKD Stage 4, we consider a 2-year risk of kidney failure of 0-10 % as low risk, 10-20 % as intermediate risk and > 20 % as high risk	

Progress To-Date and Future Directions

- Equation is accessed online > 30,000 times a month
- Decision Analysis Re: Utility as a dialysis access planning tool
- Quality Improvement Project: Utility as a consult triage tool
- External validation in diverse CKD populations

Research

Original Investigation

Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure A Meta-analysis

Navdeep Tangri, MD, PhD, FRCPC; Morgan E. Grams, MD, PhD; Andrew S. Levey, MD; Josef Coresh, MD, PhD; Lawrence J. Appel, MD; Brad C. Astor, PhD, MPH; Gabriel Chodick, PhD; Allan J. Collins, MD; Ognjenka Djurdjev, MSc; C. Raina Elley, MBCHB, PhD; Marie Evans, MD, PhD; Amit X. Garg, MD, PhD; Stein I. Hallan, MD, PhD; Lesley A. Inker, MD, MS; Sadayoshi Ito, MD, PhD; Sun Ha Jee, PhD; Csaba P. Kovesdy, MD; Florian Kronenberg, MD; Hiddo J. Lambers Heerspink, PharmD, PhD; Angharad Marks, MBBCh, MRCP, MSc, PhD; Girish N. Nadkarni, MD, MPH; Sankar D. Navaneethan, MD, MPH; Robert G. Nelson, MD, PhD; Stephanie Titze, MD, MSc; Mark J. Sarnak, MD, MS; Benedicte Stengel, MD, PhD; Mark Woodward, PhD; Kunitoshi Iseki, MD, PhD; for the CKD Prognosis Consortium

Tangri et al. JAMA 2016







Study Populations – N America

Source	Cohort	No of Participants	F/U Time, years, Median (IQI)	Age (years)	eGFR (ml/min/ 1.73m²) (SD)	Albuminuria, N (%)*	Kidney Failure Events
North	AASK**	898	8 (4, 10)	55 (11)	40 (12)	592 (66%)	303
America	ARIC	722	12 (7, 14)	67 (5)	50 (10)	192 (27%)	112
	BC CKD**	11,131	3 (2, 5)	70 (13)	31 (11)	7928 (71%)	2,091
	CCF ACR**	4,102	2 (1, 4)	71 (11)	48 (10)	1643 (40%)	101
	CCF DIP**	12,275	3 (1, 4)	72 (13)	46 (11)	2835 (23%)	300
	CRIC**	3,099	6 (4, 7)	59 (11)	40 (11)	1866 (63%)	796
	Geisinger**	20,720	4 (2, 6)	70 (10)	51 (8)	1961 (44%)	453
	ICES-KDT**	100,569	4 (2, 6)	73 (11)	46 (12)	3961 (33%)	3,093
	KEEP	16,425	4 (2, 6)	69 (12)	48 (10)	478 (32%)	500
	KPNW**	1,486	5 (3, 6)	73 (10)	45 (11)	921 (85%)	100
	MDRD**	1,459	6 (3, 12)	52 (13)	33 (14)	970 (63%)	1,041
	Mt Sinai BioMe**	3,574	2 (1, 5)	65 (13)	42 (14)	39611 (39%)	525
	Pima	78	3 (1, 5)	58 (14)	36 (15)	74 (95%)	53
	REGARDS	3,158	7 (5, 8)	72 (9)	47 (11)	1079 (36%)	240
	Sunnybrook**	3,098	3 (2, 5)	71 (14)	37 (13)	1378 (75%)	382
	VA CKD	434,810	4 (3, 4)	75 (9)	47 (11)	14084 (41%)	8,836
	Sub-Total	617,604	4 (3, 6)	74 (10)	46 (11)	79573 (41%)	18,926

Study Populations – Non NA

CRIB**	382	3 (1, 7)	61 (14)	21 (11)	259 (84%)	190
GCKD	3927	2 (2, 3)	62 (11)	42 (10)	2163 (56%)	89
GLOMMS-1	1,007	4 (1, 6)	71 (13)	31 (9)	701 (70%)	122
Gonryo	1,088	3 (1, 5)	66 (13)	32 (16)	343 (95%)	345
HUNT	1,060	13 (6, 14)	75 (8)	49 (9)	313 (30%)	55
Maccabi	58,630	5 (3, 6)	73 (11)	49 (10)	10938 (35%)	1383
MASTERPLAN**	579	6 (4, 6)	61 (12)	35 (12)	314 (54%)	134
ММКД	140	4 (2, 5)	49 (11)	30 (15)	133 (95%)	70
NephroTest**	1,317	3 (2, 6)	61 (14)	35 (13)	857 (69%)	292
NZDCS	8,865	7 (4, 8)	71 (11)	43 (15)	1099 (15%)	808
Okinawa83	1,698	17 (17, 17)	69 (10)	51 (8)	599 (35%)	55
Okinawa93	15,162	7 (7, 7)	70 (10)	52 (7)	1090 (7%)	131
RENAAL** ^{,†}	1,434	3 (2, 4)	60 (7)	37 (11)	1434 (100%)	335
Severance	3,173	10 (9, 12)	60 (10)	54 (7)	384 (12%)	92
SRR CKD**	5,291	2 (1, 3)	69 (14)	24 (9)	4335 (82%)	802
Sub-Total	103,753	4 (3, 7)	71 (12)	47 (12)	24962 (34%)	4,903
Overall Total	721,357	4 (3, 7)	74 (10)	46 (11)	104534 (40%)	23,829

Discrimination

Figure 1. Discrimination Statistics (C Statistics) for Original 4-Variable Equation at 2 Years by Cohort

ohort	C Statistic (95% CI)	Weight, %
lorth America		I
AASK	0.88 (0.83-0.93)	2.86
ARIC	0.90 (0.79-1.00)	→ 1.38
BC CKD	0.88 (0.87-0.89)	4.01
CCF ACR	0.92 (0.88-0.96)	3.33
CCF DIP ^a	0.92 (0.90-0.94)	3.78
CRIC	0.89 (0.87-0.91)	
Geisinger	0.88 (0.83-0.93)	2.90
ICES-KDT	0.94 (0.93-0.95)	4.04
KEEPa	0.96 (0.95-0.97)	- 3.97
KPNW ^a	0.94 (0.89-0.98)	2.95
MDRD	0.88 (0.87-0.90)	
Mt Sinai BioMe	0.88 (0.85-0.92)	3.45
Pima	0.85 (0.78-0.92)	2.25
REGARDS	0.92 (0.84-1.00)	→ 1.87
Sunnybrook	0.91 (0.89-0.93)	- 3.71
VA CKD	0.89 (0.87-0.90)	- 3.87
Subtotal: <i>I</i> ² = 91.3%; P<.001	0.90 (0.89-0.92)	52.08

Discrimination in Subgroups

1.0

Figure 3. Discrimination Statistics (C Statistics) for Original 4-Variable and 8-Variable Equations at 2 and 5 Years by Subgroup

A 4-Variable equation

2-Year predicted probability of kidney failure

Cohort	No. of Patients	C Statistic (95% CI)	
Diabetes			
Yes	140947	0.897 (0.869-0.924)	
No	126536	0.918 (0.898-0.937)	
Black			
Yes	13125	0.910 (0.892-0.928)	
No	236463	0.896 (0.879-0.914)	
Age, y			
≥65	196626	0.903 (0.879-0.926)	
<65	70847	0.898 (0.874-0.922)	
		_	
		0.8	0.9
			C Statistic (95% CI)

5-Year predicted probability of kidney failure No. of Cohort Patients C Statistic (95% CI) Diabetes 105343 0.881 (0.863-0.900) Yes No 118543 0.893 (0.873-0.914) Black 8997 0.884 (0.856-0.912) Yes 0.878 (0.857-0.899) No 199073 Age, y 0.885 (0.857-0.913) ≥65 162600 <65 0.874 (0.851-0.897) 61276 0.8 0.9 1.0

C Statistic (95% CI)

R 8-Variable equation

Calibration for 4-var Model (5 year)



4 Variable Equation



THE PROJECTED RISK OF KIDNEY FAILURE

Conclusions

- The KFREs accurately predict the risk of kidney failure requiring dialysis in patients with CKD Stages 3-5 for up to 5 years
- Risk prediction is accurate across multiple countries and subpopulations
- The KFRE is simple and highly accurate and can be integrated into clinical practice



Kidney Failure in Manitoba



Reporting of Kidney Function (eGFR)

- Manitoba adopted routine reporting of eGFR in Oct 2010
- A new website and referral pathways were developed in collaboration with nephrologists, primary care providers and health administrators
- An education campaign was launched to coincide with reporting of eGFR

Ryz, Tangri and Komenda, BMC Public Health: In Press

Outpatient Nephrology Referral Form

kidneyhealth.ca

Your referral will be triaged as URGENT or ELECTIVE based on 2010 Nephrology Referral Pathways criteria which are available at Manitoba Renal Program's website at www.kidneyhealth.ca/pathways or by calling 787-7382.

Referring MD: _____ Ph. ____ Fax. _____

Patient Name		Phone		
PHIN		Address		
\Box Please select ($$) either urgent or elective:	REFERRAL SITE PREFERENCE (check one)		
EMERGENT REFERRAL (< 24 HOURS) DO NOT FAX REFERRAL	eGFR <15 mL/min with indications (see referral pathway) for emergent dialysis PAGE NEPHROLOGIST ON CALL AT: Health Science Centre (204) 787-2071 St. Boniface Hospital (204) 237-2053 Brandon (204) 578-4000 or (204) 571-7139	 Health Sciences Centre Fax: (204) 787-7366 St. Boniface Hospital Fax: 204) 233-2770 Seven Oaks Hospital Fax: (204) 697-4204 Brandon Regional Fax: (204) 726-8797 Health Centre Dr 		
URGENT REFERRAL (< 4 weeks)	 Reason for Urgency (check all that apply) Hematuria, suspected GN (eGFR or proteinuria criteria below, or ANA>1:80, or decreased complements) eGFR decline by > 20% in 1-30 days Proteinuria in non-diabetic (ACR or PCR > 300 mg/mmol) 	 IMPORTANT! For us to triage your patient you must complete and append results of: Urinalysis Spot urine for ACR or PCR eGFR (also serum urea, creatinine) at least two values CBC 		
ELECTIVE REFERRAL (< 6 months)	 eGFR 30-59.9 mL/min and declining > 10 % per year eGFR < 30 mL/min Proteinuria in non-diabetic (ACR or PCR > 200 mg/mmol) Hematuria Other Reason: 	 Consider ordering and send reports when available: Serum and Urine Protein Electrophoresis (> 40 years of age) Kidney Ultrasound Please append all supporting documentation: TESTS - MEDICAL HISTORY - MEDICATIONS 		



The 2011 Manitoba Experience



*No statistically significant difference in slope or intercept (p=0.08 & p=0.77); Intercept is defined as

March 2010 for Pre GFR line of best fit and December 2010 for Post OFR line of best fit.

**Average wait time was calculated by taking weighted average weight time from four locations.

Hingwala, Tangri and Komenda CJKHD: In Press

Referral Pathways - 2011

- Site based referrals
- Urgent referrals seen within 4-8 weeks
- Semi-urgent and non-urgent referrals seen on a first come first served basis
- Median wait list time 230 days

Triage Flow Chart





*Intervention resulted in a change in # of referrals (p=0.1) and change in referral trend (slope) post-intervention (p=0.06)



*Intervention resulted in statistically significant change in wait time (p<0.001) and change in wait time trend (slope) post-intervention (p=0.029)

Discussion

- eGFR reporting led to significant increases in referrals and wait times for nephrology care in Manitoba
- Implementation of a risk based triage system reduced wait times
- Most patients triaged as low risk are unlikely to progress
- Provider satisfaction (family physician and nephrologist) with risk based triage was high

Discussion

 A risk based triage system based on the KFRE is both feasible and highly effective at improving wait times for nephrology care

• Further implementation of risk based triage and treatment pathways is the next step

How will we do this

- Revamp the Manitoba Renal Program website (kidneyhealth.ca)
- Implement automated calculating and reporting of Kidney Failure risk in all community laboratories
- Engage patients and family physicians to develop and evaluate our intervention

Revamp kidneyhealth.ca

- Report patient referral guidelines to the public with updated triage flow chart
- Patient-friendly infographics on facts and figures of CKD including KFRE calculation
- Post guidelines for management of CKD specifically depending on level of Kidney Failure risk

- Visit kidneyhealth.ca
- Click 'Primary Care'
- Referral form shortcut still available



Tool 1:

Online Kidney Disease Referral Pathway Tool



- Enter eGFR, ACR and if Hematuria present
- Click 'Next Steps'



 Get a course of action to follow whether referral or primary care management

eGFR < 15 ACR <100mg/mmol Hematuria Yes Next Steps	
RESULTS	
YOUR PATIENT HAS CKD OR AKI	
1. Discontinue nephrotoxic medications (i.e. NSAIDs).	

2. REFER TO NEPHROLOGY EMERGENT – PAGE NEPHROLOGIST AND/OR SEND PATIENT TO EMERGENCY ROOM.

3. Click for referral form/ Contact Information.

DIABETIC NEPHROPATHY MANAGEMENT GUIDELINES

NON-DIABETIC CKD MANAGEMENT GUIDELINES

muta



YES NO

If Diabetic, see <u>Diabetic Nephrology Management Guidelines</u>. If non-diabetic, see <u>Non-Diabetic</u> <u>CKD Management Guidelines</u>.

-

DIABETIC NEPHROPATHY MANAGEMENT GUIDELINES

	eGFR 15 - 59.9 • ACR >100mg/mmol • Hematuria No •
÷	e GRR + sathrand Glomentar Rinston Ran 300 + Abunh Creathra Rato
•	Next Steps
1	RESULTS
1	
	YOUR PATIENT HAS CKD OR AKI OR GLOMERULONEPHRITIS
	1 Discontinue nephrotoxic medications (i.e. NSAIDs)

<u>Refer to Nephrology</u>.



The Kidney Failure Risk Equation (KFRE) is for patients with Chronic Kidney Disease Stages 3-5 (eGFR <60). It is NOT to be used for patients with acutely declining renal function or increasing proteinuria.

4. Repeat eGFR/serum creatinine & serum electrolytes at least Q 1-4 weeks until seen by nephrology. Renal ultrasound. Forward all blood and urine test results to nephrology. Page on call nephrologist if:

- a) Acute kidney injury or acute glomerulonephritis is suspected or you are not sure.
- · b) Evidence of worsening renal function.

If Diabetic, see <u>Diabetic Nephrology Management Guidelines</u>. If non-diabetic, see <u>Non-Diabetic</u> CKD Management Guidelines.

DIABETIC NEPHROPATHY MANAGEMENT GUIDELINES

NON-DIABETIC CKD MANAGEMENT GUIDELINES

Tool 2:

Kidney Failure Risk Equation Tool

- Identifies risk of kidney failure within three and years and current stage of kidney disease (if present).
- More information available at kidneyfailurerisk.com



KIDNEY FAILURE RISK EQUATION CALCULATOR

Age	A.V		
Sex Male 💌			
GFR (MI/Min/1.73M	//2)	×	
Urine Albumin: Cr	eatinine Ratio (mg/mmol)		
Calculate			
<u>Edit</u>			
Disalation of The Mida of F		- the state of the	

Disclaimer: The Kidney Failure Risk Equation* (KFRE) is for patients with Chronic Kidney Disease Stages 3-5 (eGFR <60). It is NOT to be used for patients with acutely or sub-acutely declining renal function or increasing proteinuria.

Tool 2:

Kidney Failure Risk Equation Tool Results



Referral Form:

- Pick site
- Fax
- (Right click/save for fillable pdf)

Detailed 2016 Nephrology Referral Pathways a	re available at: www.kidi	neyhealth.ca/pathways
Referring MD:	Ph.	Fax.
Patient Name:		Phone:
PHIN:	Address:	
Please complete and append results of:	EMERGENT	eGFR <15 mL/min with indications (see
 Past medical history 	REFERRAL	referral pathway) for emergent dialysis
Medications list CER (clear communes creatining) at	(< 24 HOURS)	PAGE NEPHROLOGIST ON CALL AT:
least two values	DO NOT	Health Sciences Centre
CBC	FAX	(204) 787-2071
Urinalysis	REFERRAL	St. Boniface Hospital (204) 237-2053
 Spot urine for ACR 		Brandon
Consider and sing and condition arts		(204) 578-4000 or
when available:		(204) 571-7139
 Serum and Urine Protein 	NON-	Reason for Urgency
Electrophoresis (> 40 years of age)	EMERGENT	(check all that apply)
 Kidney Ultrasound 	LINERGENT	eGFR <30 mL/min
		KFRE >3% / 5 year
REFERRAL SITE PREFERENCE (check one)		□ eGFR decline by >20% in 1-30 days (acute kidney injury)
O Health Sciences Centre • Fax to (204) 787-7366		Proteinuria (ACR >100 mg/mmol)
Seven Oaks Hospital - Fax to (204) 697-4204 Brandon Regional Health Centre Fax to (204) 726-8797 Dr		Hematuria, suspected GN (eGFR or proteinuria criteria below, or ANA>1:80, or decreased complements, or ANCA positive or normal urological evaluation
		Other (REASON)

N.B. The noted appointment wait times are target benchmarks, but each patient will be triaged at time of referral. Appointment times may vary. Until your patient is assessed by a nephrologist, you (referring physician) are responsible for monitoring (and forwarding) your patient's blood and urine test as tregular intervals as suggested in the MRP Kinker Disease Referral Pathway. You should contact the nephrologist with any new concerns.

Engagement with Patients and Physicians

- Web site www.kidneyfailurerisk.com
- Increase Awareness of Kidney Failure risk
- Feedback from patients on how they would like Kidney Failure risk presented
- Feedback from family physicians on design of referral pathways

Patient Education Tools

THE FACTS & FIGURES OF CHRONIC KIDNEY DISEASE (CKD)

Chronic kidney disease (or CKD) is a condition where your kidneys gradually lose function over time.



Patient Education

CAUSES

The two main causes of CKD are diabetes and hypertension, which are responsible for up to two-thirds of all cases. Immune inherited causes and other reasons are responsible for the rest.



North Americans have CKD and more than 26 million have some form of the disease.

25%

North Americans over the age of 65 have some form of CKD.

.

OF

North Americans with kidney failure are awaiting kidney transplants.

i () () (

Patient Education

Risk Equation

+

RISK CALCULATION

Using the patients **Urine**, **Sex**, **Age** and **GFR**, the kidney failure risk equation provides the **2** and **5** year probability of treated kidney failure for a potential patient with CKD Stage **3** to **5**.

THE PROJECTED RISK

OF KIDNEY FAILURE

The equation has been validated in **more than 30 countries** worldwide, making it the most accurate and efficent way of finding out the patient disease levels.

COUNTRIES PARTIPATING IN VALIDATION

Deliverables

- More timely referrals of high-risk patients
- Fewer referrals of low-risk patients
- Decreased wait time to see a kidney specialist
- Cost savings for the Manitoba healthcare system

Canadian Society of Nephrology/ Société Canadienne De Néphrologie

The foundation of kidney care. Totalement dévouée aux soins du rein.

Kidney Research Scientist Core Education and National Training Program

Paul Komenda, Claudio Rigatto University of Manitoba, Department of Medicine Manitoba Renal Program